Mechanisms of TLR9 activation

Journal of Endotoxin Research

Volumn 10, Issue 6, 2004, Pages 406-412

  Latz, Eicke ^a   Visintin, Alberto ^a   Espevik, Terje ^b   Golenbock, Douglas T ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CpG DNA; Innate immunity; Phagocytosis; Toll like receptors

Indexed keywords

BACTERIAL DNA; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; VIRUS DNA;

ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CPG ISLAND; DENDRITIC CELL; ENDOPLASMIC RETICULUM; ENDOSOME; FLUORESCENCE ANALYSIS; GENE ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION;

CELL MEMBRANE; CELLS, CULTURED; CPG ISLANDS; DNA, BACTERIAL; ENDOPLASMIC RETICULUM; ESCHERICHIA COLI; HUMANS; LEUKOCYTES, MONONUCLEAR; LYSOSOMES; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

BACTERIA (MICROORGANISMS);

EID: 10244237643     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805104225006525     Document Type: Article

References (46)

1. Janeway Jr CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13: 11-16.
2. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95: 588-593.
3. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
4. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.
5. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374 546-549.
6. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
7. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptors 7 and 8. Science 2004; 303: 1526-1529.
8. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
9. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 96: 9305-9310.
10. Hartmann G, Battiany J, Poeck H et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003; 33: 1633-1641.
11. Krug A, Rothenfusser S, Hornung V et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 2154-2163.
12. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klimnan DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002; 71: 813-820.
13. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068-1070.
14. Bird AP, Taggart MH, Nicholls RD, Higgs DR. Non-methylated CpG-rich islands at the human alpha-globin locus: implications for evolution of the alpha-globin pseudogene. EMBO J 1987; 6: 999-1004.
15. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dmnt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-257.
16. Pfeifer GP, Tanguay RL, Steigerwald SD, Riggs AD. In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1. Genes Dev 1990; 4: 1277-1287.
17. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
18. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 2003; 109: 37-45.
19. Krapf F, Herrmann M, Leitmann W, Kalden JR. Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients. Clin Exp Immunol 1989; 75: 336-342.
20. Sano H, Takai O, Harata N, Yoshinaga K, Kodama-Kamada I, Sasaki T. Binding properties of human anti-DNA antibodies to cloned human DNA fragments. Scand J Immunol 1989; 30: 51-63.
21. Sano H, Imokawa M, Steinberg AD, Morimoto C. Accumulation of guanine-cytosine-enriched low M.W. DNA fragments in lymphocytes of patients with systemic lupus erythematosus. J Immunol 1983; 130 187-190.
22. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
23. Rifkin IR, Leadbetter EA, Beaudette BC et al. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol 2000; 165: 1626-1633.
24. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19: 837-847.
25. Leadbetter EA, Rifkin IR, Marshak-Rothstein A. Toll-like receptors and activation of autoreactive B cells. Curr Dir Autoimmun 2003; 6: 105-122.
26. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
27. Sandor F, Latz E, Re F et al. Importance of extra- and intracellular domains of TLR1 and TLR2 in NF-kappa B signaling. J Cell Biol 2003; 162: 1099-1110.
28. Heil F, Ahmad-Nejad P, Hemmi H et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33: 2987-2997.
29. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-198.
30. Latz E, Visintin A, Lien E et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002; 277: 47834-47843.
31. Latz E, Visintin A, Lien E, Fitzgerald KA, Espevik T, Golenbock DT. The LPS receptor generates inflammatory signals from the cell surface. J Endotoxin Res 2003; 9: 375-380.
32. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-1968.
33. Chow A, Toomre D, Garrett W, Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002; 418: 988-994.
34. Boes M, Cerny J, Massol R et al. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 2002; 418: 983-988.
35. Hacker H, Mischak H, Miethke T et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17: 6230-6240.
36. Garin J, Diez R, Kieffer S et al. The phagosome proteome: insight into phagosome functions. J Cell Biol 2001; 152: 165-180.
37. Gagnon E, Duclos S, Rondeau C et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 2002; 110: 119-131.
38. Houde M, Bertholet S, Gagnon E et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425: 402-406.
39. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425: 397-402.
40. Lehner PJ, Cresswell P. Recent developments in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 82-89.
41. Ackermann ML, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5 678-684.
42. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001; 166: 2372-2377.
43. Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev 2001; 11: 181-188.
44. Krieg AM. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Report 2004; 6: 88-95.
45. Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004; 4: 937-946.
46. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-258.